失脂症管理中的反意义寡核酸:临床试验的综述
Ikponmwosa Jude Ogieuhi1, Kristen Callender2, God-Dowell O Odukudu3
1Siberian State Medical University, Tomsk, Russia. Jude.ogieuhi@gmail.com.
概括
抗理智性寡核酸治疗在治疗脱脂症方面显示出前景,为降低像ApoB.这样的异位性脂蛋白降低提供了潜在更有效和更安全的替代方案,而不是他类药物.
科学领域:
- 生物化学和药理学 生物化学和药理学
- 心血管医学 心血管医学
- 遗传学和个性化医学
背景情况:
- 脱脂症的特点是血清脂质的异常水平,包括胆固醇和甘油三,导致动脉样硬化.
- 反感性寡核酸 (ASO) 疗法针对的关键组件,如参与低密度脂蛋白 (LDL) 代谢的阿波利波蛋白B (ApoB).
研究的目的:
- 批判性地评估Antisense Oligonucleotide治疗失脂症的疗效和安全性.
- 评估ASOs在推进个人化药物治疗失脂症管理方面的潜力.
主要方法:
- 在多个数据库中按照PRISMA指南进行系统的文献搜索.
- 包括临床试验和随机对照试验的ASOs对于dyslipidemia.
- 排除非英语研究,案例报告和评论;关键发现的叙事综合.
主要成果:
- 抗义性Oligonucleotide疗法在治疗失脂症方面显示出显著的潜力.
- 临床试验表明,与他类药物相比,ASO可以具有很高的效果,副作用最小.
- 像Mipomersen和Volanesorsen这样的特定ASO有效地降低了动脉质脂蛋白 (ApoB,ApoC-III).
结论:
- 反理性寡核酸体代表了一种有前途的新型治疗方法来治疗失脂症.
- ASO提供量身定制的治疗选择,特别是对于遗传性脂质异常患者.
- 这些疗法提供了超越传统他类药物使用的有价值的选择.
相关概念视频
01:31Lipid-derived Compounds in the Human Body
5.5K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
5.5K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741